Drug Launch Accelerator
Launch Market-Ready Therapies Faster With Connected Intelligence

Drug Launch Accelerator is a governed launch operating system that helps pharmaceutical organisations convert launch complexity into launch confidence. It connects global, regional and country launch activity into one live, role-aware view, so teams can see readiness, dependencies, risks, decisions and market execution before gaps become lost launch momentum.

Request a working demo

Proof chips

50%

of launches miss revenue forecasts, making launch execution a critical business concern.

$8M–$15M

potential monthly revenue exposure from launch delays and unresolved dependencies.

4+ Weeks

earlier visibility into critical launch risks before milestones
begin slipping.

<1 Day

target gate-review pack assembly from live readiness, not manual deck-building.

Problems It Solves

The launch plan exists across the organisation. The launch truth often does not. Siloed data, fragmented ownership, and delayed visibility turn manageable risks into launch delays. Drug Launch Accelerator creates a single source of truth for readiness, governance, and execution across every market.

Fragmented launch readiness

Readiness is scattered across spreadsheets, decks, emails, local trackers and meeting updates, making it difficult to see the real state of launch execution.

Late dependency discovery

Regulatory, access, MLR, supply, medical and commercial dependencies often surface only after they have already shifted the launch path.

Manual governance burden

Gate packs and readiness reviews consume leadership time because teams rebuild status instead of governing from live evidence.

Country-market misalignment

Global strategy and local execution can drift when countries report readiness through inconsistent formats, timelines and assumptions.

Limited launch learning

Completed launches often leave behind lessons in decks and memories, not reusable launch intelligence for the next brand, indication or market wave.

How It Solves

A governed loop from launch setup to market execution. Drug Launch Accelerator provides a structured framework to onboard products, markets, and launch strategies, orchestrate cross-functional activities, monitor readiness, govern critical decisions, and maintain complete traceability. By unifying planning, execution, compliance, and governance, it helps pharmaceutical teams deliver compliant, coordinated, and successful product launches across global markets.

Onboard

Capture launch context, countries, product modality, playbooks and source material in a structured launch setup flow.

Plan

Instantiate launch clocks, workstreams, activities, dependencies, market waves and governance gates from a governed launch model.

Monitor

Track readiness, blockers, risks and downstream dependency movement from live activity updates.

Govern

Run gate decisions with owners, rationale, evidence, conditions and audit trail.

Prove

Show who changed what, when, why and from which source, so launch decisions are traceable.

Learn

Convert launch execution history into reusable lessons, playbooks and institutional knowledge.

Core Capabilities

Everything launch leaders need to see, decide and prove. Drug Launch Accelerator provides a unified view of launch readiness, cross-functional execution, governance, risks, and dependencies across products and markets. By combining operational visibility with decision traceability, it enables pharmaceutical teams to accelerate launches, mitigate delays, and demonstrate compliance and accountability at every stage of the launch lifecycle.

Launch Command Centre

Portfolio, market and wave visibility across readiness, launch health, risks, blockers, gates and leadership attention areas.

Launch Readiness Workspace

Country and workstream readiness across regulatory, market access, medical, commercial, supply, quality and local execution.

Governance and Gate Management

Go/no-go decisions, RACI, escalations, assumptions, dependency management, conditions, rationale and audit history.

Dependency and Risk Intelligence

Critical-path visibility that shows what is slipping, what it affects and who needs to act before the impact escalates.

Human-Governed Launch Intelligence

Source-linked recommendations, summaries and setup support that assist teams while accountable people remain in control.

Post-Launch Learning

A structured learning layer that turns launch experience into reusable benchmarks, playbooks and future launch readiness intelligence.

Outcomes

Move from reactive reporting to launch confidence. Drug Launch Accelerator equips pharmaceutical launch teams with the visibility, governance, and intelligence needed to proactively manage risks, accelerate decision-making, and improve launch readiness. By turning fragmented launch activities into a coordinated operating model, it helps organizations achieve more predictable, compliant, and successful product launches across global markets.

Earlier risk visibility

Give launch teams time to intervene before critical dependencies become launch delays.

Faster governance readiness

Reduce manual gate-pack preparation by running reviews from live launch data and traceable evidence.

Stronger cross-functional alignment

Bring global, regional, country and workstream teams into one shared launch operating model.

Clearer executive decisions

Surface the markets, gates, risks and blockers that require leadership attention.

Higher launch discipline

Make readiness measurable, ownership visible and decisions auditable.

Reusable launch intelligence

Carry lessons, patterns and playbook improvements into the next launch.

Infocepts Drug Launch Accelerator Outcomes Overview

KNOW MORE

Personas / Departments

Global Launch Leaders

Launch readiness, gate status, critical-path dependencies, blockers, mitigations and decision history.

Country and Regional Teams

Local readiness, market-specific activities, country blockers, launch wave status and go/no-go inputs.

Regulatory Teams

Submission, label, packaging, health authority milestones and country-level dependency context.

Market Access Teams

HTA, pricing, reimbursement, payer milestones and access-driven launch sequencing risks.

Commercial and Medical Teams

Field readiness, campaign readiness, content approval status, medical engagement and evidence-readiness visibility.

Quality, PV and Supply Teams

Release readiness, safety obligations, distribution readiness, supply checkpoints and market availability constraints.

Integrations & Deployment

Integration-ready by design: Designed to sit above systems such as regulatory, MLR, ERP, CRM, finance, data platforms and document repositories, while preserving their role as systems of record. Configurable launch model: Launch clocks, countries, market waves, modalities, readiness weights, gates and governance logic can be adapted to different organisations and launch archetypes.

Role-scoped access: Users see the information relevant to their role, market, workstream and governance responsibility. Audit-ready traceability: Critical changes, gate decisions, recommendations and approvals are recorded with ownership and context. Human-governed intelligence: AI can recommend, summarise and support launch setup, but accountable people decide.

Partner Ecosystem

Drug Launch Accelerator connects with a trusted ecosystem of pharmaceutical, regulatory, commercial, and technology partners to streamline launch operations and improve market readiness. By integrating data, workflows, and governance across the launch landscape, these partnerships help organizations accelerate execution, reduce risk, and deliver successful product launches with greater confidence and control.

LEARN MORE

Resources

Explore insights, case studies, and expert perspectives on pharmaceutical launch readiness, governance, and market execution. These resources highlight how launch teams are reducing risk, accelerating governance, and driving measurable launch confidence.

Blog

Drug Launch Accelerator Launch Market-Ready Therapies Faster With Connected Intelligence

Proof chips

50%

$8M–$15M

4+ Weeks

<1 Day

Problems It Solves

Fragmented launch readiness

Late dependency discovery

Manual governance burden

Country-market misalignment

Limited launch learning

How It Solves

Onboard

Plan

Monitor

Govern

Prove

Learn

Core Capabilities

Launch Command Centre

Launch Readiness Workspace

Governance and Gate Management

Dependency and Risk Intelligence

Human-Governed Launch Intelligence

Post-Launch Learning

Outcomes

Personas / Departments

Global Launch Leaders

Country and Regional Teams

Regulatory Teams

Market Access Teams

Commercial and Medical Teams

Quality, PV and Supply Teams

Integrations & Deployment

Partner Ecosystem

Resources

10 best Databricks Migration Partners for Life Sciences and Pharma Companies

The Future of Pharma Commercial Excellence: From Data to Decision Intelligence

How Pharma Commercial Operations Analytics Linked Marketing to Sales?

10 Best Databricks Consulting Services for Life Sciences and Pharmaceutical Companies

One Launch, 10,000 Different Buyers: How Pharma Key Account Profiling Won Them Over

10 Best Data Engineering Service Providers for Life Sciences and Pharma Companies in 2026

The Future of Pharma Commercial Excellence

$43,686 in Recurring Annual Savings. Zero Performance Trade-Offs

What’s Really Slowing Down Your Biopharma Launch: The Science or the Spreadsheet?

Pharma Commercial Data Silos: Why It’s Not an Analytics Problem

15% Lower Costs and 20% Faster Delivery in 8 Months: The Business Case for an AI-Ready Supply Chain Data Platform

Life Sciences Analytics That Actually Move Commercial Results

The Pilot Phase Is Over: Why Pharma’s AI Strategy Needs an Overhaul in 2026

The Future of AI in Pharma: 6 Shifts Across the Lifecycle

PMSA 2026 – Turning AI Momentum into Measurable, Sustainable Advantage in Life Sciences

Boosting Planning Speed, Visibility, and ROI with Unified AI Insights

The Data Platform Modernization Playbook for Life Sciences: Cloud, Governance, and AI Readiness

KOL Identification at Scale: Why Machine Learning Outperforms Business Rules

How AI Is Reshaping Medical Affairs: From MSL Reporting to Scientific Intelligence

Cell & Gene Therapy Order Management: Connecting the Complex Patient Journey

Improving Patient Adherence with Real-Time Analytics: A Data-First Approach

Payer Intelligence in the Age of AI: How to Optimize Market Access Before Day One

Supply Chain Intelligence Platform Driving 10% Cost Savings and 12% Delivery Gains

From Silos to Synergy: How Omnichannel Analytics Transforms HCP Engagement

Why Pharma Commercial Teams Need a Connected Intelligence Layer – Not More Dashboards

The 90-Day Drug Launch Intelligence Playbook: What Leading Biotechs Do Differently

A Guide to AI-Powered Synthetic Control Arms: Driving Ethical Innovation and Operational Excellence

AI-Powered Field Salesforce Transformation for a Global Pharma Leader

Predictive Maintenance for Clean-In-Place (CIP) Systems

Why Traditional HCP Engagement Fails—and How AI is Changing the Game

A Guide to AI-Powered HCP Engagement: Driving Precision, Performance & Patient Impact

Empowering Global Inventory Operations with Accelerated Insights via Incorta

The Language of Care: Unlocking Patient Sentiment with AI

Decode the Patient Voice with AI: Transform Unstructured Data into Strategic Pharma Insights

Future of Life Sciences with Agentic AI: From Discovery to Patient Care

Cutting Costs and Boosting Performance with Predictive Supply Chain Analytics

Proactive Supply Chain Management in Life Sciences through Real-Time Insights and AI

Assistive vs Agentic AI in Life Sciences: Use Cases & Learnings

E6: Assistive vs. Agentic AI in Life Sciences: Use Cases & Learnings

AI in Life Sciences: A Practical Guide for Pharma Leaders

Episode 6: Assistive vs. Agentic AI in Life Sciences: Use Cases & Learnings

AI-Powered Insights on Dataiku Improves Cancer Treatment Outcomes

Empowering Pharma Growth with Advanced Market Access Analytics

Drug Launch Accelerator
Launch Market-Ready Therapies Faster With Connected Intelligence